Migraine affects roughly one billion people globally, yet its underlying biology remains poorly understood — a gap that shapes why treatments frequently fall short. A convergent mechanistic framework now implicates the brain's waste-clearance architecture, not merely pain-signaling pathways, as a central driver of migraine initiation and recurrence, potentially reframing how the condition is approached therapeutically.
This review in Frontiers in Immunology synthesizes emerging evidence that the glymphatic system — a perivascular network dependent on aquaporin-4 (AQP-4) water channels expressed at astrocyte endfeet — becomes functionally impaired in migraine. Cerebrospinal fluid normally flows through peri-arterial spaces, crosses into interstitial fluid via AQP-4, and drains to cervical lymph nodes via meningeal lymphatic vessels (MLVs). In mouse models of migraine induced by nitroglycerin, this clearance cascade is disrupted, leading to accumulation of calcitonin gene-related peptide (CGRP), reactive oxygen species, and pro-inflammatory mediators. A key mechanistic detail is that cortical spreading depression — the electrophysiological wave underlying migraine aura — transiently closes perivascular spaces, acutely impairing glymphatic flux. CGRP further compounds dysfunction within MLVs by promoting VE-cadherin rearrangement, restricting CSF efflux and amplifying neuroinflammatory signaling.
This framework is intellectually important because it positions migraine not as a discrete pain event but as a condition partly maintained by impaired neuroimmune waste management — a lens already gaining traction in Alzheimer's and sleep-disorder research. The glymphatic system's dependence on deep sleep for peak function adds another mechanistic bridge, aligning with the well-documented clinical observation that sleep disruption both triggers and follows migraine attacks. Critically, all cited mechanistic data originate from rodent models, and translating glymphatic physiology to living human brains remains technically challenging; non-invasive imaging proxies exist but lack validation. This is a hypothesis-generating review rather than a clinical trial, so causality between glymphatic dysfunction and human migraine onset is not yet established. Still, the convergence of AQP-4, CGRP, and MLV biology into a single mechanistic axis offers genuinely novel therapeutic targets beyond existing gepant and ditriptan drug classes.
